Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers

Journal of Clinical Pharmacology

Volumn 51, Issue 5, 2011, Pages 695-705

  Peterschmitt, M Judith ^a   Burke, Amy ^a   Blankstein, Larry ^a   Smith, Sharon E ^a,c   Puga, Ana Cristina ^a   Kramer, William G ^b   Harris, James A ^c   Mathews, David ^d   Bonate, Peter L ^a,e  

^a GENZYME CORPORATION   (United States)

^b Kramer Consulting LLC   (United States)

^c Quintiles ^*  (United Kingdom)

^d IQVIA   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Cerezyme; Gaucher disease; glucosylceramide synthase inhibitor; lysosomal storage disorder; substrate reduction therapy

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; CYTOCHROME P450 2D6; ELIGLUSTAT TARTRATE; GENZ 112638; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; APPETITE; ARTICLE; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG URINE LEVEL; DRY SKIN; DYSGEUSIA; ELECTROCARDIOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PR INTERVAL; QRS COMPLEX; QT INTERVAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; THROAT IRRITATION; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; DIZZINESS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FEMALE; FOOD-DRUG INTERACTIONS; GLUCOSYLTRANSFERASES; HEART RATE; HUMANS; INTESTINAL ABSORPTION; MALE; MODELS, BIOLOGICAL; NAUSEA; PYRROLIDINES; VOMITING; YOUNG ADULT;

EID: 77957601016     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010372387     Document Type: Article

References (14)

1. Beutler E, Grabowski G The Metabolic and Molecular Bases of Inherited Disease. Scriver CR Beaudet A Sly W, ed. New York: McGraw-Hill ; 2001: 3635-3668.
2. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002 ; 113: 112-119 (Pubitemid 34804747)
3. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000 ; 355: 1481-1485 (Pubitemid 30237353)
4. Elstein D, Hollak C, Aerts JM, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis. 2004 ; 27: 757-766 (Pubitemid 39433603)
5. Allschwil, Switzerland: Actelion Pharmaceuticals, Ltd ; 2008 :
6. Platt FM, Neises GR, Karlsson GB, Dwek RA, Butters TD. N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem. 1994 ; 269: 27108-27114
7. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem. 1999 ; 274: 14662-14669
8. Vunnam RR, Radin NS. Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem Phys Lipids. 1980 ; 26: 265-278
9. McEachern KA, Fung J, Komarnitsky S, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab. 2007 ; 91: 259-267 (Pubitemid 46819125)
10. Food-Effect Bioavailability and Fed Bioequivalence Studies. Rockville, MD: FDA ; 2002 :
11. Gough K, Hutcheson M, Keene O, et al. Assessment of dose proportionality: report from the Statisticians in the Pharmaceutical Industry PK UK Joint Working Party. Drug Inf J. 1995 ; 29: 1039-1048
12. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J. 2005 ; 7: E609 - E624
13. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Preliminary concept paper draft 4. Rockville, MD: FDA ; 2004 :
14. Lukina E, Watman N, Arreguin EA, et al. A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010 ; 116: 893-899